Arbutus licensee Alnylam posts positive Phase 3 results

Arbutus licensee Alnylam posts positive Phase 3 results

Arbutus Biopharma’s (NASDAQ:ABUS) lipid nanoparticle (LNP) licensee, Alnylam Pharmaceuticals (NASDAQ:ALNY), announced that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint and all secondary endpoints.

Read More

Mackie starts Promis at speculative buy

Mackie starts Promis at speculative buy

Mackie Research Capital initiated coverage of Promis Neurosciences (TSX:PMN) with a “speculative buy” rating and price target of 50 cents, saying the company has a promising new path to target Alzheimer’s disease (AD). The stock closed at 25 cents on Sept. 18.

Read More

BTIG cuts Tactile Systems to neutral

BTIG cuts Tactile Systems to neutral

BTIG downgraded Tactile Systems Technology (NASDAQ:TCMD) to “neutral” from “buy,” saying the stock is up more than 100% year-to-date, exceeding its price target of $35. The stock closed at $36.79 on Sept. 15.

Read More

MaRS Innovation in collaboration with Evotec AG

MaRS Innovation in collaboration with Evotec AG

MaRS Innovation and Evotec AG (FSE:EVT) have launched LAB150, a Toronto-based partnership to tap infrastructure and drug discovery expertise of Evotec and drug discovery projects from the 15-member institutions of MaRS.

Read More

HCW cuts Applied Genetic price target to $8

HCW cuts Applied Genetic price target to $8

H.C. Wainwright slashed its price target for Applied Genetic Technologies (NASDAQ:AGTC) to $8 from $16 but maintained its “buy” rating after the company posted financing results below consensus for the fiscal year ended June 30, 2017 and updated its clinical programs.

Read More

HCW starts Collegium at buy

HCW starts Collegium at buy

H.C. Wainwright initiated coverage of Collegium Pharmaceuticals (NASDAQ:COLL) with a “buy” rating and $21 price target. The stock closed at $10.21 on Sept. 8.

Read More

BTIG cuts NeoGenomics to neutral

BTIG cuts NeoGenomics to neutral

BTIG downgraded NeoGenomics (NASDAQ:NEO) to “neutral” from “buy,” citing hurricanes that have hit Texas and Florida and noting that the shares are near its $11 price target, almost reaching an all-time high. The stock closed at $10.64 on Sept. 8.

Read More

Ortho RTi CSO appointed bioengineering chair at George Mason

Ortho RTi CSO appointed bioengineering chair at George Mason

Ortho Regenerative Technologies said its chief scientific officer, Michael Buschmann, has been appointed as bioengineering chair, professor and eminent scholar (an award from Virginia's Center for Innovative Technology) at George Mason University in Fairfax, VA. 

Read More

IntelGenx film process does not infringe MonoSol patent

IntelGenx film process does not infringe MonoSol patent

IntelGenx (TSXV:IGX; OTCQX:IGXT) announced that a decision by the U.S. District Court for the District of Delaware determined that the process used to manufacture IntelGenx's and Par Pharmaceutical's buprenorphine/naloxone sublingual film product for the treatment of opiate addiction does not infringe MonoSol Rx U.S. Patent No. 8,900,497. 

Read More